Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.
暂无分享,去创建一个
Y. Erdi | S. Larson | M. Gönen | H. Schöder | H. Yeung | A. Noy | David Green | L. Weng
[1] Mithat Gonen,et al. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] R. Hicks,et al. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. , 2003, Clinical lymphoma.
[3] A. Alavi,et al. Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.
[4] U. Jäger,et al. F-Fluorodeoxyglucose Positron Emission Tomography ( 18 F-FDG-PET ) for Staging and Follow-Up of Marginal Zone B-Cell Lymphoma , 2003 .
[5] M. Pepe. The Statistical Evaluation of Medical Tests for Classification and Prediction , 2003 .
[6] Mithat Gonen,et al. Diagnostic and Prognostic Value of [18F]Fluorodeoxyglucose Positron Emission Tomography for Recurrent Head and Neck Squamous Cell Carcinoma , 2002 .
[7] P. Dupont,et al. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] F. O’Sullivan,et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[9] Michael E. Phelps,et al. Effect of Whole-Body 18F-FDG PET Imaging on Clinical Staging and Management of Patients with Malignant Lymphoma , 2001 .
[10] R. Hustinx,et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] J Kotzerke,et al. 2‐(fluorine‐18)fluoro‐2‐deoxy‐D‐glucose positron emission tomography in the detection and staging of malignant lymphoma , 2001, Cancer.
[12] Sung-Cheng Huang,et al. Anatomy of SUV , 2000 .
[13] G Flandrin,et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] P. Dupont,et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Coleman,et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma , 1998, Cancer.
[16] M Schwaiger,et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. , 1998, Blood.
[17] Y. Koide,et al. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] H. Yagata,et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2‐deoxy‐2‐fluoro[18F]‐D‐glucose , 1998, Cancer.
[19] J. D. van der Walt,et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. , 1998, Blood.
[20] S. Reske,et al. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] E. Merkle,et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. , 1998, Radiology.
[22] S M Larson,et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding , 1997, Cancer.
[23] G. Salles,et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M E Phelps,et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] Y. Chung,et al. F-Fluorodeoxyglucose Positron Emission Tomography and the Prognosis of Patients with Pancreatic Adenocarcinoma , 1997 .
[26] H. Minn,et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. , 1995, Blood.
[27] B. Glimelius,et al. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] K. Någren,et al. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[29] Rosenberg Sa. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. , 1977 .
[30] Y. Erdi,et al. Standardized uptake value in pediatric patients: an investigation to determine the optimum measurement parameter , 2001, European Journal of Nuclear Medicine and Molecular Imaging.
[31] J. Diebold,et al. Lymphoma classification--from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.